These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10702274)

  • 21. Inhibition of HIV protease activity by heterodimer formation.
    Babé LM; Pichuantes S; Craik CS
    Biochemistry; 1991 Jan; 30(1):106-11. PubMed ID: 1988010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
    Karnati KR; Wang Y
    J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV protease as a target for retrovirus vector-mediated gene therapy.
    Todd S; Anderson C; Jolly DJ; Craik CS
    Biochim Biophys Acta; 2000 Mar; 1477(1-2):168-88. PubMed ID: 10708857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thermodynamic analysis of dimerization inhibitors binding to HIV protease monomers].
    Ershov PV; Gnedenko OV; Mol'nar AA; Lisitsa AV; Ivanov AS; Archakov AI
    Biomed Khim; 2012; 58(1):43-9. PubMed ID: 22642151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folded monomer of HIV-1 protease.
    Ishima R; Ghirlando R; Tözsér J; Gronenborn AM; Torchia DA; Louis JM
    J Biol Chem; 2001 Dec; 276(52):49110-6. PubMed ID: 11598128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.
    Babé LM; Rosé J; Craik CS
    Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10069-73. PubMed ID: 7479728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.
    Dufau L; Marques Ressurreição AS; Fanelli R; Kihal N; Vidu A; Milcent T; Soulier JL; Rodrigo J; Desvergne A; Leblanc K; Bernadat G; Crousse B; Reboud-Ravaux M; Ongeri S
    J Med Chem; 2012 Aug; 55(15):6762-75. PubMed ID: 22800535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
    Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
    Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.
    Dautin N; Karimova G; Ladant D
    J Virol; 2003 Aug; 77(15):8216-26. PubMed ID: 12857890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
    Wu X; Liu H; Xiao H; Conway JA; Kappes JC
    J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases.
    Babé LM; Rosé J; Craik CS
    Protein Sci; 1992 Oct; 1(10):1244-53. PubMed ID: 1338945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
    Grant SK; Deckman IC; Minnich MD; Culp J; Franklin S; Dreyer GB; Tomaszek TA; Debouck C; Meek TD
    Biochemistry; 1991 Aug; 30(34):8424-34. PubMed ID: 1883829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
    Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R; Levy Y; Tiana G
    Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.
    Velazquez-Campoy A; Muzammil S; Ohtaka H; Schön A; Vega S; Freire E
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):311-28. PubMed ID: 14754432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
    Wang YF; Tie Y; Boross PI; Tozser J; Ghosh AK; Harrison RW; Weber IT
    J Med Chem; 2007 Sep; 50(18):4509-15. PubMed ID: 17696515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
    Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
    Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.
    Kräusslich HG
    J Virol; 1992 Jan; 66(1):567-72. PubMed ID: 1727499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.